You are currently viewing a new version of our website. To view the old version click .

Advances in Vaccines and Antimicrobial Therapy—2nd Edition

Topic Information

Dear Colleagues,

This topic is a second edition of “Advances in Vaccines and Antimicrobial Therapy”. Our first edition has published 20 papers with a total of 37474 views. You can read the latest papers at: https://www.mdpi.com/topics/X66IH7XM49. Now we have set up a second edition and look forward to receiving more submissions.

The fields of prevention and treatment of infectious diseases have been gaining momentum after the outbreak of the coronavirus pandemic, with several advances both in vaccine technology and in the development of new antimicrobials. The usefulness of monoclonal antibodies has been tested, along with several old and new compounds with antiviral activity, but the search for new avenues, combining diverse strategies and reexamining older drugs for potential new activities, is quickly evolving. Interactions of drugs with the local microbiota, combinations of systemic approaches, targeting immune defense mechanisms together with arresting microbial host invasion, refinements in nano-formulations, drug delivery, rapid genotyping of microorganisms, and engineering of bacteriophages in the fight against multidrug resistance are just some of the areas in which breakthrough research is expected to bring significant advances in the near future.

The aim of this Topic is to offer an updated view of the advances in all the fields of antimicrobial therapy and prevention. This Topic collection invites contributions of research articles, reviews, and meta-analyses, exploring the new horizons of antimicrobial therapy and vaccine development. Both in vitro and in vivo studies, field studies, and reports, as well as bold new hypotheses based on original observations, are also welcome. We, as Editors, expect both academic research institutions and industry research to be represented in this collection on issues of primary relevance for health systems and individual safety in the near future.

Dr. Raffaele D’Amelio
Dr. Roberto Paganelli
Topic Editors

Keywords

  • drug delivery
  • phage therapy
  • antibiotic resistance
  • antivirals
  • vaccine technology

Participating Journals

Biomolecules
Open Access
12,198 Articles
Launched in 2011
4.8Impact Factor
9.2CiteScore
19 DaysMedian Time to First Decision
Q1Highest JCR Category Ranking
Cells
Open Access
19,647 Articles
Launched in 2012
5.2Impact Factor
10.5CiteScore
16 DaysMedian Time to First Decision
Q2Highest JCR Category Ranking
International Journal of Molecular Sciences
Open Access
105,686 Articles
Launched in 2000
4.9Impact Factor
9.0CiteScore
20 DaysMedian Time to First Decision
Q1Highest JCR Category Ranking
Parasitologia
Open Access
191 Articles
Launched in 2021
1.5Impact Factor
2.4CiteScore
18 DaysMedian Time to First Decision
Q3Highest JCR Category Ranking
Pathogens
Open Access
8,827 Articles
Launched in 2012
3.3Impact Factor
6.8CiteScore
13 DaysMedian Time to First Decision
Q2Highest JCR Category Ranking
Vaccines
Open Access
9,549 Articles
Launched in 2013
3.4Impact Factor
9.9CiteScore
20 DaysMedian Time to First Decision
Q2Highest JCR Category Ranking
Biologics
Open Access
129 Articles
Launched in 2021
-Impact Factor
7.2CiteScore
24 DaysMedian Time to First Decision
-Highest JCR Category Ranking
Microorganisms
Open Access
16,702 Articles
Launched in 2013
4.2Impact Factor
7.7CiteScore
15 DaysMedian Time to First Decision
Q2Highest JCR Category Ranking

Published Papers